Chronic musculoskeletal pain: pathogenesis, clinical features, therapy possibilities
https://doi.org/10.30629/0023-2149-2022-100-11-12-527-534
Abstract
The control of musculoskeletal pain (MSP) is an important part of the complex treatment of rheumatic diseases (RD). Analgesic therapy still plays the leading role in osteoarthritis (OA) and chronic nonspecific back pain (most cases of this syndrome are associated with spinal OA) treatment. Despite the use of modern basic anti-inflammatory drugs (including biological and JAK inhibitors), the problem of MSP control remains relevant in immuno-inflammatory diseases, such as rheumatoid arthritis and spondyloarthritis. The pathogenesis of MSP is complex and closely related to the processes of damage, inflammation and degeneration. A fundamental role here belongs to local and systemic inflammatory response occurrence, which largely determines such elements of the pathogenesis of chronic MSP as peripheral and central sensitization. Depending on the prevailing pathogenesis mechanisms, MSP can manifest itself in several phenotypes: «inflammatory», «mechanical», «enthesopathic», associated with central sensitization. A combination with such symptoms as stiffness, fatigue, muscle tension, sleep disturbance, depression and anxiety is characteristic for MSP. The control should be comprehensive and must include the use of both drug and drug-free preparations. Nonsteroidal anti-inflammatory drugs, opioids, muscle relaxants, antidepressants and anticonvulsants, local injection therapy (glucocorticoids, hyaluronic acid, platelet-rich plasma), as well as methods of physiotherapy and rehabilitation are used in pain treatment.
About the Author
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Karateev Andrey E.
115522, Moscow
References
1. Karateev A.E., Nasonov E.L. Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):197–209. (In Russian). DOI: 10.14412/1995-4484-2019-197-209
2. Puntillo F., Giglio M., Paladini A. et al. Pathophysiology of musculoskeletal pain: a narrative review. Ther. Adv. Musculoskelet Dis. 2021;13:1759720X21995067. DOI: 10.1177/1759720X21995067
3. Nasonov E.L., Yakhno N.N., Karateev A.E. et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):247–265 (In Russian). DOI: 10.14412/1995-4484-2016-247-265
4. Zhuang J., Mei H., Fang F., Ma X. What Is New in Classification, Diagnosis and Management of Chronic Musculoskeletal Pain: A Narrative Review. Front Pain Res (Lausanne). 2022;3:937004. DOI: 10.3389/fpain.2022.937004
5. Albrecht K., Marschall U., Callhoff J. Verordnung von Schmerzmitteln bei Patienten mit rheumatischen Erkrankungen in Deutschland: Eine Analyse von Abrechnungsdaten [Prescription of analgesics in patients with rheumatic diseases in Germany: A claims data analysis. German version]. Z Rheumatol. 2021; 80(3):243–250. German. DOI: 10.1007/s00393-021-00962-z
6. Anastasiou C., Yazdany J. Review of publications evaluating opioid use in patients with inflammatory rheumatic disease. Curr. Opin. Rheumatol. 2022;34(2):95–102. DOI: 10.1097/BOR.0000000000000868
7. Hallberg S., Rolfson O., Karppinen J. et al. Burden of disease and management of osteoarthritis and chronic low back pain: healthcare utilization and sick leave in Sweden, Norway, Finland and Denmark (BISCUITS): study design and patient characteristics of a real world data study. Scand. J. Pain. 2022;20. DOI: 10.1515/sjpain-2021-0212
8. Salucci S., Falcieri E., Battistelli M. Chondrocyte death involvement in osteoarthritis. Cell. Tissue Res. 2022;389(2):159–170. DOI: 10.1007/s00441-022-03639-4
9. Yang J., Hu S., Bian Y., Yao J., Wang D., Liu X., Guo Z., Zhang S., Peng L. Targeting Cell Death: Pyroptosis, Ferroptosis, Apoptosis and Necroptosis in Osteoarthritis. Front. Cell. Dev. Biol. 2022;9:789948. DOI: 10.3389/fcell.2021.789948
10. Khir NAM, Noh ASM, Long I. et al. Inflammatory-associated apoptotic markers: are they the culprit to rheumatoid arthritis pain? Mol. Biol. Rep. 2022;49(10):10077–10090. DOI: 10.1007/s11033-022-07591-y
11. Arendt-Nielsen L., Morlion B., Perrot S. et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur. J. Pain. 2018;22(2):216–41. DOI: 10.1002/ejp.1140
12. Mauceri D. Role of epigenetic mechanisms in chronic pain. Cells. 2022;11(16):2613. DOI: 10.3390/cells11162613
13. Tsuda M. Microglia-mediated regulation of neuropathic pain: molecular and cellular mechanisms. Biol. Pharm. Bull. 2019;42(12):1959–1968. DOI: 10.1248/bpb.b19-00715
14. Hiraga S.I., Itokazu T., Nishibe M., Yamashita T. Neuroplasticity related to chronic pain and its modulation by microglia. Inflamm Regen. 2022;42(1):15. DOI: 10.1186/s41232-022-00199-6
15. Duffield S., Miller N., Zhao S., Goodson N. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(8):1453–1460. DOI: 10.1093/rheumatology/key112
16. Zolio L., Lim K.Y., McKenzie J.E. et al. Systematic review and meta-analysis of the prevalence of neuropathic-like pain and/or pain sensitization in people with knee and hip osteoarthritis. Osteoarthritis Cartilage. 2021;29(8):1096–1116. DOI: 10.1016/j.joca.2021.03.021
17. Meade E., Garvey M. The Role of Neuro-immune interaction in chronic pain conditions; functional somatic syndrome, neurogenic inflammation, and peripheral neuropathy. Int. J. Mol. Sci. 2022;23(15):8574. DOI: 10.3390/ijms23158574
18. Cohen S.P., Vase L., Hooten W.M. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397(10289):2082–2097. DOI: 10.1016/S0140-6736(21)00393-7
19. Van Spil W.E., Kubassova O., Boesen M. et al. Osteoarthritis phenotypes and novel therapeutic targets. Biochem Pharmacol. 2019;165:41–48. DOI: 10.1016/j.bcp.2019.02.037
20. Pan F., Jones G. Clinical perspective on pain and pain phenotypes in osteoarthritis. Curr. Rheumatol. Rep. 2018;20(12):79. DOI: 10.1007/s11926-018-0796-3
21. McGonagle D., Hermann K.G., Tan A.L. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford). 2015;54(1):29–38. DOI: 10.1093/rheumatology/keu328
22. Juneja S.C., Veillette C. Defects in tendon, ligament, and enthesis in response to genetic alterations in key proteoglycans and glycoproteins: a review. Arthritis. 2013;2013:154812. DOI: 10.1155/2013/154812
23. Kim H.J., Ban M.G., Yoon K.B., Jeon W., Kim S.H. Neuropathic-like pain symptoms and their association with muscle strength in patients with chronic musculoskeletal pain. J. Clin. Med. 2022;11(18):5471. DOI: 10.3390/jcm11185471
24. Karateev A.E., Lila A.M. et al. Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis. Rheumatology Science and Practice. 2022;60(4):427–437. (In Russian). DOI: 10.47360/1995-4484-2022-427-437
25. Pogozheva E.Yu., Karateev A.E., Bulgakova N.A., Amirdzhanova V.N., Filatova E.S., Nesterenko V.A., Lila A.M. Satisfaction with analgesic therapy in patients with rheumatic diseases in real clinical practice, according to the KOMPAS study (quality of pain relief in the opinion of patients with arthritis and back pain). Modern Rheumatology Journal. 2021;15(4):43–49. (In Russian). DOI: 10.14412/1996-7012-2021-4-43-49
26. da Costa B.R., Pereira T.V., Saadat P. et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021;375:n2321. DOI: 10.1136/bmj.n2321
27. Smith S.R., Deshpande B.R., Collins J.E., Katz J.N., Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962–72. DOI: 10.1016/j.joca.2016.01.135
28. Derry S., Conaghan P., Da Silva J.A., Wiffen P.J., Moore R.A. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016;4(4):CD007400. DOI: 10.1002/14651858.CD007400.pub3
29. Rannou F., Pelletier J.P., Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin. Arthritis Rheum. 2016;45(4):S18–21. DOI: 10.1016/j.semarthrit.2015.11.007
30. Leopoldino A.O., Machado G.C., Ferreira P.H. et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst. Rev. 2019;2:CD013273. DOI: 10.1002/14651858.CD013273
31. Abdel Shaheed C., Awal W., Zhang G. et al. Efficacy, safety, and dose-dependence of the analgesic effects of opioid therapy for people with osteoarthritis: systematic review and meta-analysis. Med. J. Aust. 2022;216(6):305–311. DOI: 10.5694/mja2.51392
32. Coluzzi F., Fornasari D., Pergolizzi J., Romualdi P. From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur. Rev. Med. Pharmacol. Sci. 2017;21(7):1672–1683.
33. Abdel Shaheed C., Maher C.G., Williams K.A., McLachlan A.J. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. Eur. J. Pain. 2017;21(2):228–237.
34. Urits I., Li N., Berardino K., Artounian K.A. et al. The use of antineuropathic medications for the treatment of chronic pain. Best Pract. Res. Clin. Anaesthesiol. 2020;34(3):493–506. DOI: 10.1016/j.bpa.2020.08.007
35. Weng C., Xu J., Wang Q., Lu W., Liu Z. Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a Systematic review and meta-analysis. Osteoarthritis Cartilage. 2020;28(6):721–734. DOI: 10.1016/j.joca.2020.03.001
36. Welsch P., Üçeyler N., Klose P. et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst. Rev. 2018;2(2):CD010292. DOI: 10.1002/14651858.CD010292.pub2
37. Davydov O.S., Yakhno N.N., Kukushkin M.L., etc. Neuropathic pain: clinical guidelines for the diagnosis and treatment of the Russian Society for the Study of Pain. Russian Journal of Pain. 2018;4(58):5–41. (In Russian). DOI: 10.25731/RASP.2018.04.025
38. Migliorini F., Maffulli N., Knobe M., Tenze G., Aljalloud A., Colarossi G. Pregabalin administration in patients with fibromyalgia: a Bayesian network meta-analysis. Sci. Rep. 2022;12(1):12148. DOI: 10.1038/s41598-022-16146-x
39. Jüni P., Hari R., Rutjes A.W. et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst. Rev. 2015;(10):CD005328. DOI: 10.1002/14651858.CD005328.pub3
40. Coombes B.K., Bisset L., Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010;376(9754):1751–67. DOI: 10.1016/S0140-6736(10)61160-9
41. Samuels J., Pillinger M.H., Jevsevar D., Felson D., Simon L.S. Critical appraisal of intra-articular glucocorticoid injections for symptomatic osteoarthritis of the knee. Osteoarthritis Cartilage. 2021;29(1):8–16. DOI: 10.1016/j.joca.2020.09.001
42. Gupta R.C., Lall R., Srivastava A., Sinha A. Hyaluronic acid: molecular mechanisms and therapeutic trajectory. Front Vet. Sci. 2019; 6:192. DOI: 10.3389/fvets.2019.00192
43. Cooper C., Rannou F., Richette P. et al. Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clinical practice. Arthritis Care Res. (Hoboken). 2017;69(9):1287–1296. DOI: 10.1002/acr.23204
44. Khan M., Shanmugaraj A., Prada C., Patel A., Babins E., Bhandari M. The role of hyaluronic acid for soft tissue indications: a systematic review and meta-analysis. Sports Health. 2022;3:19417381211073316. DOI: 10.1177/19417381211073316
45. McLarnon M., Heron N. Intra-articular platelet-rich plasma injections versus intra-articular corticosteroid injections for symptomatic management of knee osteoarthritis: systematic review and meta-analysis. BMC Musculoskelet Disord. 2021;22(1):550. DOI: 10.1186/s12891-021-04308-3
46. Karateev A.E., Sukhareva M.V., Lila A.M. Medical rehabilitation in the combination treatment of rheumatic diseases: a review. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(5):584–596 (In Russian). DOI: 10.14412/1995-4484-2019-584-596
47. Zhang H., Wang B., He J., Du Z. Efficacy and safety of radiofrequency ablation for treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. J. Int. Med. Res. 2021;49(4):3000605211006647. DOI: 10.1177/03000605211006647
48. Knotkova H., Hamani C., Sivanesan E., Le Beuffe M.F.E., Moon J.Y., Cohen S.P., Huntoon M.A. Neuromodulation for chronic pain. Lancet. 2021;397(10289):2111–2124. DOI: 10.1016/S0140-6736(21)00794-7
49. O’Connell N.E., Marston L., Spencer S., DeSouza L.H., Wand B.M. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst. Rev. 2018;4(4):CD008208. DOI: 10.1002/14651858.CD008208.pub5
50. O’Neill A., Lirk P. Multimodal Analgesia. Anesthesiol. Clin. 2022;40(3):455–468. DOI: 10.1016/j.anclin.2022.04.002
Review
For citations:
Karateev A.E. Chronic musculoskeletal pain: pathogenesis, clinical features, therapy possibilities. Clinical Medicine (Russian Journal). 2022;100(11-12):527-534. (In Russ.) https://doi.org/10.30629/0023-2149-2022-100-11-12-527-534
Views:
759
Email this article 